The agenda for the 5 November 2014 Transparency Commission is now available. The Commission will consider the listing of the following medicines:

• Pitavastatin calcium (Trolise) - new medicine
• Vedolizumab (Entyvio) - new medicine
• Lenalidomide (Revlimid) - new indication
• Lenalidomide (Revlimid) - new strength

For more details, go to:  http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-10/odj_ct_05112014_internet.pdf [French]